Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

被引：0
|
作者：
Amoozgar, Behzad [1 ]
Bangolo, Ayrton, I [2 ]
Uesole, David H. [3 ,4 ]
Siegel, David S. [5 ,6 ]
Biran, Noa [3 ]
Phull, Pooja [3 ]
Donato, Michele L. [7 ]
Parmar, Harsh [3 ]
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA
[3] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[4] Medstar GeorgetownMed Ctr, Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[6] Ctr Discovery & Innovat, Hackensack, NJ USA
[7] Hackensack Meridian Hlth, John Theurer Canc Ctr, Stem Cell Transplantat & Cellular Therapy Program, Hackensack, NJ USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-211671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2408 / 2409
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
    Dileo, Rachel
    Mewawalla, Prerna
    Patrus, Gina
    Strouse, Christopher
    Chen, Ethan
    Shaikh, Hira
    Davis, James A.
    Green, Kimberly M.
    Alkharabsheh, Omar
    Rashid, Aliya
    Pokhrel, Bidushi
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2024, 144 : 4742 - 4743
  • [32] A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
    Habib, Alma
    Khan, Abdullah Mohammad
    Laharwal, Mehak M.
    Mewawalla, Prerna
    Mckenna, Marshall
    Tiger, Yun Kyoung
    Shaikh, Hira
    Strouse, Christopher
    Green, Kimberly M.
    Davis, James A.
    Hashmi, Hamza
    Snyder, Jordan
    Mahmoudjafari, Zahra
    Mushtaq, Muhammad Umair
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Atrash, Shebli
    Paul, Barry
    Friend, Reed
    BLOOD, 2024, 144 : 7037 - 7038
  • [33] A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
    Rocchi, Serena
    Tacchetti, Paola
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    di Giovanni Bezzi, Chiara
    Scalese, Marco
    Dozza, Luca
    Marzocchi, Giulia
    Martello, Marina
    Barila, Gregorio
    Antonioli, Elisabetta
    Staderini, Michela
    Buda, Gabriele
    Petrini, Mario
    Cea, Michele
    Quaresima, Micol
    Furlan, Anna
    Bonalumi, Angela
    Cavo, Michele
    Zamagni, Elena
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 41 - 50
  • [34] The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience
    Charlinski, Grzegorz
    Grzasko, Norbert
    Jurczyszyn, Artur
    Janczarski, Mariusz
    Szeremet, Agnieszka
    Waszczuk-Gajda, Anna
    Bernatowicz, Pawel
    Swiderska, Alina
    Guzicka-Kazimierczak, Renata
    Lech-Maranda, Ewa
    Szczepaniak, Andrzej
    Wichary, Ryszard
    Dmoszynska, Anna
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (03) : 354 - 361
  • [35] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Buthainah Ghanem
    Lu Shi
    Clinical Drug Investigation, 2022, 42 : 1085 - 1092
  • [36] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [37] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    CLINICAL DRUG INVESTIGATION, 2022, 42 (12) : 1085 - 1092
  • [38] Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
    Nishihori, Taiga
    Hoffman, James E.
    Huff, Anne
    Kapoor, Gurpreet S.
    Eleftheriadou, Ioanna
    Zajic, Stefan
    Urbano, Alisa
    Suchindran, Sunil
    Chisamore, Michael
    D'Souza, Jimson W.
    Faitg, Thomas
    Rapoport, Aaron P.
    BLOOD ADVANCES, 2023, 7 (07) : 1168 - 1177
  • [39] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
    Berdeja, Jesus G.
    Raje, Noopur S.
    Siegel, David S.
    Lin, Yi
    Anderson, Larry D., Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Einsele, Hermann
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy B.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [40] Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma (vol 37, pg 1779, 2021)
    Martin, Tom
    Usmani, Saad Z.
    Schecter, Jordan M.
    Vogel, Martin
    Jackson, Carolyn C.
    Deraedt, William
    Tian, Hong
    Yeh, Tzu-min
    Banerjee, Arnob
    Pacaud, Lida
    Garrett, Ashraf
    Haltner, Anja
    Cameron, Chris
    Van Sanden, Suzy
    Diels, Joris
    Valluri, Satish
    Samjoo, Imtiaz A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (12) : 2197 - 2208
12345